Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (46)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Walsh, S.
Right arrow Articles by Beresford, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, S.
Right arrow Articles by Beresford, J. N.
Related Collections
Right arrow Osteoporosis and Metabolic Bone Disease
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 74-83
© 2001 British Society for Rheumatology

High concentrations of dexamethasone suppress the proliferation but not the differentiation or further maturation of human osteoblast precursors in vitro: relevance to glucocorticoid-induced osteoporosis

S. Walsh, G. R. Jordan1, C. Jefferiss, K. Stewart and J. N. Beresford

Bone Research Group, Department of Pharmacy and Pharmacology, 7 West, University of Bath, Claverton Down, Bath BA2 7AY and
1 Bone Research Group, Department of Medicine, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK

Objective. The use of glucocorticoids (GCs) in the treatment of RA is a frequent cause of bone loss. In vitro, however, this same class of steroids has been shown to promote the recruitment and/or maturation of primitive osteogenic precursors present in the colony forming unit-fibroblastic (CFU-F) fraction of human bone and marrow. In an effort to reconcile these conflicting observations, we investigated the effects of the synthetic GC dexamethasone (Dx) on parameters of growth and osteogenic differentiation in cultures of bone marrow stromal cells derived from a large cohort of adult human donors (n=30).

Methods. Marrow suspensions were cultured in the absence and presence of Dx at concentrations between 10 pm and 1 µm. After 28 days we determined the number and diameter of colonies formed, the total number of cells, the surface expression of receptors for selected growth factors and extracellular matrix proteins and, based on the expression of the developmental markers alkaline phosphatase (AP) and the antigen recognized by the STRO-1 monoclonal antibody, the proportion of cells undergoing osteogenic differentiation and their extent of maturation.

Results. At a physiologically equivalent concentration, Dx had no effect on the adhesion of CFU-F or on their subsequent proliferation, but did promote their osteogenic differentiation and further maturation. These effects were independent of changes in the expression of the receptors for fibroblast growth factors, insulin-like growth factor 1, nerve growth factor, platelet-derived growth factors and parathyroid hormone/parathyroid hormone-related protein, but were associated with changes in the number of cells expressing the {alpha}2 and {alpha}4, but not ß1, integrin subunits. At supraphysiological concentrations, the effects of Dx on the osteogenic recruitment and maturation of CFU-F and their progeny were maintained but at the expense of a decrease in cell number.

Conclusions. A decrease in the proliferation of osteogenic precursors, but not in their differentiation or maturation, is likely to be a key factor in the genesis of GC-induced bone loss.

KEY WORDS: Glucocorticoid-induced osteoporosis, Osteoblasts, Bone marrow stromal cells, Dexamethasone, Colony-forming unit, STRO-1, Alkaline phosphatase, Flow cytometry, Growth factor receptors, Integrins.

Correspondence to: S. Walsh


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev., April 1, 2008; 29(2): 155 - 192.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F.-S. Wang, J.-Y. Ko, D.-W. Yeh, H.-C. Ke, and H.-L. Wu
Modulation of Dickkopf-1 Attenuates Glucocorticoid Induction of Osteoblast Apoptosis, Adipocytic Differentiation, and Bone Mass Loss
Endocrinology, April 1, 2008; 149(4): 1793 - 1801.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. P. Kirton, F. L. Wilkinson, A. E. Canfield, and M. Y. Alexander
Dexamethasone Downregulates Calcification-Inhibitor Molecules and Accelerates Osteogenic Differentiation of Vascular Pericytes: Implications for Vascular Calcification
Circ. Res., May 26, 2006; 98(10): 1264 - 1272.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. E. Phillips, C. A. Gersbach, A. M. Wojtowicz, and A. J. Garcia
Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation
J. Cell Sci., February 1, 2006; 119(3): 581 - 591.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F.-S. Wang, C.-L. Lin, Y.-J. Chen, C.-J. Wang, K. D. Yang, Y.-T. Huang, Y.-C. Sun, and H.-C. Huang
Secreted Frizzled-Related Protein 1 Modulates Glucocorticoid Attenuation of Osteogenic Activities and Bone Mass
Endocrinology, May 1, 2005; 146(5): 2415 - 2423.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
N. J. Minaur, C. Jefferiss, A. K. Bhalla, and J. N. Beresford
Methotrexate in the treatment of rheumatoid arthritis. I. In vitro effects on cells of the osteoblast lineage
Rheumatology, July 1, 2002; 41(7): 735 - 740.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.